top of page
  • info268792

Cievert | X-Europe Startup Interview

Welcome to the second article of our X-Europe startup interview series. We have virtually sat down with a number of our founders from past cohorts to hear all about their solutions, vision for the future and what made them tick during our X Europe programme. So whether you are a deep tech founder looking for startup support, an eagle-eyed investor or simply interested in the possibilities that technology can bring to society, then we welcome you to take a read. Next for your consideration - Cievert.

Hi, What is your name? Hi, my name is Alex Blakoe, Chief Operating Officer of Cievert.

Can you briefly explain what your solution is all about? What’s unique about it?

We are using AI to optimise the diagnosis and treatment of patients, helping improve and save countless lives.

We started off by developing software for managing specialist clinical pathways. We do things like automating referrals, monitoring patients remotely, standardising reporting... This helps patients get better treatment faster and helps hospitals work more efficiently.

Our solutions have been capturing plenty of rich, structured patient data along the way, so we use machine learning to derive insight from that data. This helps us further improve our solutions, as well as helping support research in the life sciences sector.

How can your solution impact the Health sector?

Data in healthcare exists in vast quantities, but unfortunately, it is of poor quality for any use other than delivering treatment directly to a patient. What we've done is developed digital solutions that are used by clinicians and happen to capture data in a rich, structured way.

By collecting high-quality data, we can therefore support research into developing new treatments and we can help optimise existing treatments. For example, we learn what works for a certain type of patient and we can therefore personalise treatment for future patients who are similar. This helps to reduce side-effects, reduce mortality, improve outcomes, and so on.

Since the foundation of your company, what has been its biggest milestones? What challenges are you still trying to overcome?

We have managed to gain traction in many clinical areas. For example, our solutions now manage 25% of the UK's cancer patients receiving radiotherapy, which is a milestone of which we are very proud.

More recently, we were selected as one of the companies supporting the rollout of the Covid vaccine in the UK. We have since taken thousands of bookings from patients, which is really exciting.

What was the status of your product before joining X-Europe? How has your original product vision evolved?

Prior to X-Europe, we were focused on the UK, and in particular the NHS. Since joining X-Europe, we have started to work across Europe, securing contracts with multinationals looking to implement our solutions outside of the UK.

After joining and benefiting from the services X-Europe has provided to you, what next steps do you envision?

We expect to build on this international traction and scale our team in order to do so. We will continue to work with hospitals, universities, and corporations globally to support our vision of using data to transform healthcare.

What tips do you have for entrepreneurs trying to succeed in the HealthTech/BioTech field?

It is extremely important to work closely with the people who will be using your product. We make a point of engaging the clinicians and patients who will be the end-users, and we often find that they become champions of our products. This helps not only to ensure our products work for their intended purpose but also helps us grow our business through word-of-mouth.

What’s unique about the X-Europe programme?

The X-Europe programme is far more comprehensive than other accelerators. It really brings together all aspects of support, from product mentoring to investor introductions to marketing workshops.


For up to date information on X-Europe, follow us today on Twitter, Instagram, and LinkedIn.


bottom of page